Table 2 The correlation between activities of uMMP-9 dimer with different uMMPs examined in bladder cancer patients
uMMPs | MMP-9 dimer (%) | Total | Measurement of agreement | p-value | |
|---|---|---|---|---|---|
| Â | Negative | Positive | Â | Â | Â |
| Â | (31) | (53) | Â | (kappa test) | Â |
MMP-2 | Â | Â | Â | Â | Â |
Negative | 26 (83.9) | 4 (11.4) | 30 | Â | Â |
Positive | 5 (16.1) | 31 (88.6) | 36 | 0.726 | <0.001 |
MMP-9 | Â | Â | Â | Â | Â |
Negative | 24 (77.4) | 1 (2.9) | 25 | Â | Â |
Positive | 7 (22.6) | 34 (97.1) | 41 | 0.754 | <0.001 |
MMP-9/NGAL | Â | Â | Â | Â | Â |
Negative | 25 (80.6) | 1 (2.9) | 26 | Â | Â |
Positive | 6 (19.4) | 34 (97.1) | 40 | 0.785 | <0.001 |
MMP-9/TIMP | Â | Â | Â | Â | Â |
Negative | 29(93.5) | 29 (82.9) | 58 | Â | Â |
Positive | 2 (6.5) | 6 (17.1) | 8 | 0.102 | >0.05 |
ADAMTS-7 | Â | Â | Â | Â | Â |
Negative | 26 (83.9) | 23 (65.7) | 49 | Â | >0.05 |
Positive | 5 (16.1) | 12 (34.3) | 17 | 0.176 | Â |